Cell Therapeutics, Inc. (CTIC) announced that the U.S. Food and Drug Administration's or FDA Oncologic Drugs Advisory Committee or ODAC will review CTI's New Drug Application or NDA for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma on March 22, 2010.
The company said that the meeting was to take place on February 10, 2010, but the FDA postponed the meeting because of severe weather conditions in the Washington, D.C. area. Following the vote at the rescheduled ODAC meeting, the FDA is expected to make a final decision on approval of CTI's NDA for pixantrone by April 23, 2010.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.